Crescent Biopharma Inc.
CBIO | NASDAQ
$12.96
-$0.52 (-3.86%)
Nov 2, 2026, 12:42 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 | Q1 2024 Mar 31, 2024 | Q4 2023 Dec 31, 2023 | Q3 2023 Sep 30, 2023 | Q2 2023 Jun 30, 2023 | Q1 2023 Mar 31, 2023 | Q4 2022 Dec 31, 2022 | Q3 2022 Sep 30, 2022 | Q2 2022 Jun 30, 2022 | Q1 2022 Mar 31, 2022 | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | 1.04M | 10.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 10K | n/a | n/a | n/a | n/a | n/a | 75K | n/a | 17.63K | 86.56K | 142 | 1.06M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | 1.04M | 10.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 10K | n/a | n/a | n/a | n/a | n/a | 75K | n/a | 17.63K | 86.56K | 142 | 1.06M |
Operating Income | -26.36M | -24.73M | -91.49M | -25.89M | -21.03M | -14.22M | -17.19M | -11.23M | -10.36M | -11.12M | -9.59M | -9.81M | -8.93M | -10.94M | -10.62M | -8.77M | -13.35M | -14.66M | -17.43M | -17.34M | -14.4M | -14.28M |
Interest Income | 1.53M | 1.45M | 1.1M | 1.28M | 313K | 188K | 176K | 184.52K | 262.29K | 378.36K | 512.19K | 610.98K | 671.03K | 581.67K | 378.27K | 243.6K | 85.59K | 7.07K | 4.08K | 4.63K | 5.22K | 5.85K |
Pretax Income | -24.84M | -23.28M | -90.4M | -24.61M | -21.79M | -15.15M | -17.87M | -9.82M | -10.1M | -10.74M | -9.08M | -9.2M | -8.26M | -10.36M | -10.24M | -8.52M | -13.27M | -14.65M | -17.42M | -17.33M | -14.4M | -14.27M |
Net Income | -22.69M | -23.28M | -92.4M | -24.61M | -21.79M | -15.15M | -17.87M | -9.82M | -10.1M | -10.74M | -9.08M | -9.2M | -8.26M | -10.36M | -10.24M | -8.52M | -13.27M | -14.65M | -17.42M | -17.33M | -14.4M | -14.27M |
Selling & General & Admin | 8.74M | 7.87M | 7.31M | 5.54M | 8.95M | 3.6M | 3.16M | 4.01M | 4.07M | 5.09M | 4.31M | 4.52M | 4.86M | 5.52M | 4.73M | 3.85M | 5.46M | 5.06M | 4.55M | 4.14M | 4.24M | 4.19M |
Research & Development | 19.39M | 17.9M | 95.03M | 20.35M | 12.08M | 10.63M | 14.03M | 1.72M | 6.29M | 6.03M | 5.29M | 5.29M | 4.07M | 5.42M | 5.89M | 4.92M | 7.97M | 9.6M | 12.9M | 13.28M | 10.17M | 11.15M |
Other Expenses | -1.77M | n/a | n/a | n/a | n/a | n/a | n/a | 5.51M | -40 | n/a | 382 | -294 | 237 | 312 | 799 | -421 | -123 | 188 | -404 | -48 | 342 | 110 |
Operating Expenses | 26.36M | 25.77M | 102.34M | 25.89M | 21.03M | 14.22M | 17.19M | 11.23M | 10.36M | 11.12M | 9.6M | 9.81M | 8.93M | 10.94M | 10.62M | 8.77M | 13.43M | 14.66M | 17.44M | 17.42M | 14.4M | 15.34M |
Interest Expense | n/a | n/a | n/a | n/a | 1.07M | 1.11M | 852K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 26.36M | 25.77M | 102.34M | 25.89M | 21.03M | 14.22M | 17.19M | 11.23M | 10.36M | 11.12M | 9.6M | 9.81M | 8.93M | 10.94M | 10.62M | 8.77M | 13.43M | 14.66M | 17.44M | 17.42M | 14.4M | 15.34M |
Income Tax Expense | n/a | n/a | 2M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 30.53M | 30.4M | 20.17M | 16.54M | 3.86M | 771.85K | 644.84K | 644.84K | 644.84K | 644.57K | 643.94K | 643.5K | 642.76K | 603.5K | 529.62K | 524.24K | 524.07K | 523.31K | 520.12K | 515.65K | 515.39K | 506.97K |
Shares Outstanding (Diluted) | 30.53M | 30.4M | 20.17M | 16.54M | 3.86M | 771.85K | 644.84K | 644.84K | 644.84K | 644.57K | 643.94K | 643.5K | 642.76K | 603.5K | 529.62K | 524.24K | 524.07K | 523.31K | 520.12K | 515.65K | 515.39K | 506.97K |
EPS (Basic) | -0.74 | -0.77 | -4.58 | -1.49 | -5.65 | -19.63 | -27.71 | -15.24 | -15.66 | -16.66 | -14.10 | -14.30 | -12.85 | -17.17 | -19.34 | -16.26 | -25.32 | -28 | -33.50 | -33.61 | -27.94 | -28.16 |
EPS (Diluted) | -0.74 | -0.77 | -4.58 | -1.49 | -5.65 | -19.63 | -27.71 | -15.24 | -15.66 | -16.66 | -14.10 | -14.30 | -12.85 | -17.17 | -19.34 | -16.26 | -25.32 | -28 | -33.50 | -33.61 | -27.94 | -28.16 |
EBITDA | -24.77M | -23.22M | -90.34M | -24.58M | -20.72M | -14.04M | 18.12M | -5.71M | -10.35M | -11.1M | -9.57M | -9.77M | -8.89M | -10.9M | -10.58M | -8.72M | -13.3M | -14.6M | -17.36M | -17.27M | -14.34M | -14.21M |
EBIT | -24.84M | -23.28M | -90.4M | -24.61M | -20.72M | -14.04M | -17.02M | -5.72M | -10.36M | -11.12M | -9.59M | -9.81M | -8.93M | -10.94M | -10.62M | -8.77M | -13.35M | -14.66M | -17.43M | -17.34M | -14.4M | -14.28M |
Depreciation & Amortization | 66K | 64K | 54K | 28K | 2K | n/a | 35.14M | 8.13K | 12.42K | 14.62K | 23.3K | 42.75K | 43.42K | 43.84K | 45.72K | 47.35K | 54.77K | 59.31K | 61.64K | 67.38K | 67.49K | 68.09K |
Add to Watchlist
Select watchlists to add or remove CBIO